Pharmacyclics Plans Xcytrin NDA Based On New Data Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Overall Phase III results for motexafin in brain metastases failed to meet endpoints but additional analyses found positive results from U.S. trial group.
You may also be interested in...
Pharmacyclics Gets “Refuse To File” Letter On Xcytrin
Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.
Pharmacyclics Eyes Priority Review For NSCLC Treatment
CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.
Pharmacyclics Eyes Priority Review For NSCLC Treatment
CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.